Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 150-159

  Butt, A A ^a,b,c,d   Ren, Y ^a   Marks, K ^d   Shaikh, O S ^a,e   Sherman, K E ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HAMAD MEDICAL CORPORATION   (Qatar)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; RITONAVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; FEMALE; FIB 4 SCORE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; KIDNEY DISEASES;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; RISK FACTORS; RITONAVIR; SIMEPREVIR; SOFOSBUVIR;

EID: 85002136615     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13837     Document Type: Article

References (31)

1. FDA. FDA approves Viekira Pak to treat hepatitis C. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm (accessed 6 March 2016).
2. FDA. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm (accessed 6 March 2016).
3. Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015; 60: 1031–5.
4. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2016; 64: 790–9.
5. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016; 64: 234–8.
6. Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med 2015; 373: 1886–8.
7. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015; 149: 1315–7.
8. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2009; 30: 240–50.
9. Butt AA, Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease. Am J Kid Dis 2011; 57: 396–402.
10. Erqou S, Mohanty A, McGinnis KA, et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. J Viral Hepat 2013; 20: 463–9.
11. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol 2013; 11: 741–7.
12. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int 2015; 36: 651–8.
13. Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis 2015; 15: 510.
14. Rogal SS, Yan P, Rimland D, et al. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES. Dig Dis Sci 2015; 61: 930–6.
15. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015; 22: 691–700.
16. Butt AA, Yan P, Lo Re V 3rd, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175: 178–85.
17. Butt AA, Yan P, Bonilla H, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 2015; 62: 365–74.
18. Butt AA, McGinnis KA, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 1227–34.
19. Lo RV III, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20: 689–99.
20. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973–82.
21. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983–92.
22. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603.
23. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604–14.
24. Lawitz E, Makara M, Akarca US, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 2015; 149: 971–80. e1.
25. Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62: 1037–46.
26. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016; 36(Suppl. 1): 47–57.
27. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 2016; 64: 301–7.
28. Khatri A, Menon RM, Marbury TC, et al. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 2015; 63: 805–12.
29. FDA. Harvoni product label approved by FDA. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf (accessed 7 March 2016).
30. FDA. Simeprevir product label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf (accessed 7 March 2016).
31. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631–57.